We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug & Device Products
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Publications
    • Webinar Training Pass
    • eCFR and Guidances
    • Books
  • Clinical Products
  • Advertising
  • White Papers
  • Contact Us
  • About Us
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Beckman Coulter Gets Expanded BARDA Agreement for Sepsis Test

Beckman Coulter Gets Expanded BARDA Agreement for Sepsis Test

Test Tubes, computer Screen, testing
May 19, 2020

Beckman Coulter has expanded its partnership with HHS’ Biomedical Advanced Research and Development Authority (BARDA) to study the use of the company’s sepsis diagnostic in COVID-19 patients.

The FDA cleared the sepsis diagnostic in April 2019 for use with Dascena’s electronic health record algorithm to predict and detect patients with sepsis.

The aim of the new study is to determine whether the test can aid in the detection of sepsis regardless of whether it is bacterial or viral-induced.

View today's stories

Medical Devices COVID-19 Research and Development

Upcoming Events

  • 24May

    Powering an Effective Oversight Strategy with Clinical and Operational Insights

  • 25May

    2022 WCG Avoca Quality & Innovation Summit: Own the Future

  • 21Jun

    Medical Device Reporting: Best Practices and Common Pitfalls

  • 22Jun

    Meet CDRH’s New Strategic Priorities: Where the Center is Headed and How Devicemakers Can Keep Up

  • 28Jun

    Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

Featured Products

  • Biological Risk Evaluation and Management for Medical Devices

  • GMP Inspection Preparation Checklist: A Tool for Internal Auditing

Featured Stories

  • Linear Health Sciences Gets FDA Clearance for Its Orchid Safety Release Valve

  • Roche’s Faricimab Gains UK Approval Via International Program

  • Becton Dickinson Gets FDA Clearance for Its Molecular Diagnostic Platform

  • Bayer Backs Out of $670 Million Collaboration Deal With Atara

The Revised ICH E8: A Guide to New Clinical Trial Requirements

Learn More
  • Drug Products
    • Quality
    • Regulatory Affairs
    • GMPs
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Device Products
    • Quality
    • Regulatory Affairs
    • QSR
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Clinical Products
    • Trial Design
    • Data Integrity
    • GCP
    • Inspections and Audits
    • Transparency
  • Privacy Policy
  • Do Not Sell My Personal Information
Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Fax 703.538.7676 – Toll free 888.838.5578

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing